|
Dr. Christoffersen is a general partner at Morgenthaler Ventures, and prior to that was most recently the President and CEO of Ribozyme Pharmaceuticals, Inc., a biotechnology company whose mission is to commercialize the Nobel Prize-winning discovery of ribozymes for use as human therapeutics. He was formerly the Senior Vice President of Research at SmithKline Beecham, and Vice President of Discovery Research at The Upjohn Company, and President of Colorado State University. Christoffersen received an honorary doctor of law degree from Cornell College in 1983, the "Outstanding Research of the Year" Award from the International Society of Quantum Biology in 1981, and the "W. E. Upjohn Award" for contributions in biotechnology in 1988. He received his bachelor's degree in chemistry and mathematics from Cornell College, and Ph.D. in chemistry from Indiana University. Based in Boulder, Colorado, he is focusing on new biotechnology investments. | 